ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / INM / news
PTN (35) CURX (37) MBRX (34) BFRG (32) ⌘ Pro Terminal →

Why INM Stock surged +3.07% Today — RQD Quant Desk Flash

$1.68 +3.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.69

InMed Pharmaceuticals Inc. (INM) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $9.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, InMed Pharmaceuticals Inc. (NASDAQ: INM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.68 (+3.07% 1D, market cap $9.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, INM ranks #317 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INM compare to PTN and CURX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INM carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 34.5%, and ROIC of -35.0%. By comparison, PTN (Palatin Technologies Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $8.9M) and CURX (Curanex Pharmaceuticals Inc) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $9.2M). Among the 5-stock peer group, INM leads on earnings multiple (N/A) while INM leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INM?
▼

Per INM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001728328), InMed Pharmaceuticals Inc. generated $4.9M in revenue (+7.5% YoY), -$8.2M in net income, and -$8.1M in free cash flow against $11.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.69 (+0.36%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (6)Whales (13)SEC (11)Macro (12)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-4.8% Base Target
$2 Bull$2 Base$1 Bear
📬 FREE INM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INM)Realized 20D OHLCV Swing Band: ±11.1%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY INM SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (28% of score)

20D Institutional Volume Accumulation (±11.1% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)

FRED Regime × Technicals: 63% of 52W Range • RSI-14 at 69.2 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$1.31+3.8% Next Q
Q2 (-2Q)
42
Grade D$1.36+17.6% Next Q
Q3 (-1Q)
44
Grade D$1.60+5% Next Q
Current
47
Grade D$1.68-5.9% Hist 90D α
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INM currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.39) and Max Pain ($1.76) forces dealer call-delta covering toward $2.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INM Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why INM Stock surged +3.07% Today — RQD Quant Desk Flash

InMed Pharmaceuticals Inc. (INM) surged +3.07% to $1.68, trading at 63% of its 52-week range ($0.57 – $2.33). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 63% of its 52-week range ($0.57 – $2.33) with RSI-14 at 69.2 (BULLISH MOMENTUM).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±11.1% around $1.68 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D (Sell) backed by 34.5% gross margin and $0 annual free cash flow.
Live INM Headlines & Catalysts
RISK WATCHYahoo • 20d ago
How Much Downside Is Left In Liquidia Stock?

Over the past month, shares of Liquidia (LQDA) have lost 59%, even as the S&P 500 gained 2.5%. Reuters reported that the stock dropped nearly 50% on September 30 after a federal judge ruled that Yutrepia, Liquidia's inha

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INM)

  • ✓Walkthrough of INM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
INM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +127.03%⚡ TESTING RESISTANCE
2026-11-04O $1.60H $1.68L $1.60C $1.68VOL 140.6K
RES: $1.68SUP: $1.14SMA50: $1.39SMA200: $1.21
$2.45$1.95$1.46$0.96$0.47RES $1.68SUP $1.14$1.682026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INM Butterfly Map → + Track INM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +7.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on INM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INM)

Health Care Rank #317 of 1015 ⚔️ PTN vs INM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INM vs. PTN, CURX, MBRX, BFRG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, InMed Pharmaceuticals Inc. (INM) ranks #317 by composite RQD confidence (47/100, grade D) and #900 by equity capitalization ($9.0M). Within this direct 5-issuer industry benchmark cohort, INM leads on earnings valuation at N/A trailing P/E, while INM leads on capital efficiency and profitability with -35.0% ROIC and 34.5% gross margin. INM currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
INM ACTIVE
InMed Pharmaceuticals Inc.
D 47/100 — 34.5% -35.0% +3.07% $9.0M Benchmark Subject
PTN
Palatin Technologies Inc.
D- 35/100 — — -35.0% +4.61% $8.9M /ptn-vs-inm →
CURX
Curanex Pharmaceuticals Inc
D- 37/100 — — -35.0% +5.81% $9.2M /curx-vs-inm →
MBRX
Moleculin Biotech Inc.
E 34/100 — — -35.0% -0.24% $8.7M /mbrx-vs-inm →
BFRG
Bullfrog AI Holdings Inc.
E 32/100 — 18.8% -35.0% +5.40% $9.2M /bfrg-vs-inm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001728328 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), InMed Pharmaceuticals Inc. (INM) reported GAAP revenue of $4.9M (+7.5% vs. FY2024 revenue of $4.6M , and +19.5% cumulative change since FY2023) , GAAP net income of -$8.2M, operating cash flow of -$8.1M, and free cash flow of -$8.1M (-15.8% YoY). On the balance sheet, INM closed FY2025 with $11.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $4.9M -$8.2M -$8.1M -$8.1M $11.2M —
FY2024 (FY) 2024-06-30 $4.6M -$7.7M -$7.0M -$7.0M $8.5M —
FY2023 (FY) 2023-06-30 $4.1M -$7.9M -$7.3M -$7.3M — —

3. INM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, InMed Pharmaceuticals Inc. (NASDAQ: INM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.68 (+3.07% 1D, market cap $9.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, INM ranks #317 in composite RQD confidence.

How does INM compare to PTN and CURX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INM carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 34.5%, and ROIC of -35.0%. By comparison, PTN (Palatin Technologies Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $8.9M) and CURX (Curanex Pharmaceuticals Inc) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $9.2M). Among the 5-stock peer group, INM leads on earnings multiple (N/A) while INM leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INM?

Per INM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001728328), InMed Pharmaceuticals Inc. generated $4.9M in revenue (+7.5% YoY), -$8.2M in net income, and -$8.1M in free cash flow against $11.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INM trading relative to its 50-day, 200-day, and 52-week technical levels?

INM last traded at $1.68 (+3.07% on volume of 174,848 shares), positioning the stock +20.86% above its 50-day simple moving average ($1.39) and +38.84% above its 200-day simple moving average ($1.21). Across its 52-week range of $0.57 to $2.33, INM sits at the 63.1% percentile with a 14-day RSI of 69.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.1% ($1.49 to $1.87).

Direct Sub-Reports: INM RQD Cockpit INM 12M Forecast INM Earnings & Move INM Dividends & DRIP INM Insiders & 13F INM Whale Options INM Profit Sankey INM News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

INM — InMed Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

InMed Pharmaceuticals Inc. (INM) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.68 (+3.07% 1D, market capitalization $9.0M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 34.5%, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

InMed Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the market data, gross margin is 34.5%, operating margin is 0%, and net margin is -60%. FY 2025 revenue was $4.9M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), InMed Pharmaceuticals Inc. (INM) reported $4.9M in annual revenue (up from $4.6M in FY2024, +7.5% YoY) and -$8.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($4.1M revenue, -$7.9M net income) through FY2025, INM scaled operating cash flow to -$8.1M and free cash flow to -$8.1M, backed by $11.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 13/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $0.57 – $2.33 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the provided data.

  • Key Question #1: Can INM sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $4.9M and free cash flow of -$8.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is INM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

INM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for InMed Pharmaceuticals Inc. (INM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INM Bull vs. Bear Conversation Board — What's Your Call at $1.68?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on INM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $2.03 (+26.9%)
📌 Pinned Debate

Reported cash rose to $7.0M in FY 2025 from $3.4M in FY 2024 while revenue grew from $4.1M to $4.9M across the reported periods.

Reported cash rose to $7.0M in FY 2025 from $3.4M in FY 2024 while revenue grew from $4.1M to $4.9M across the reported periods.. When you look under the hood at INM, Fundamental Cash Engine is 6/20 with 34.5% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (13/20) has been quietly accumulating below $2.33. My 12M target is $2.03.

SectorRotator 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (34.5%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $1.31 (-18.1%)
Spot @ $1.60

ROIC of -35%, net margin of -60%, and FCF yield of 0% indicate the business is not currently generating returns on capital or free cash

Here is the bear case nobody on the bull side wants to address on INM: ROIC of -35%, net margin of -60%, and FCF yield of 0% indicate the business is not currently generating returns on capital or free cash flow.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE